The US Food and Drug Association (FDA) expands use of Novartis drug Promacta to include treatment of children ages one and older with chronic immune thrombocytopenia (ITP)
The updated label also includes a new oral suspension formulation of Promacta
The FDA has approved an expanded use for Promacta (eltrombopag) to include children one year of age and older with (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Promacta was approved by the FDA as a tablet formulation in June 2015 for children six years of age and older and in 2008 for use in adult patients with the same condition.
The updated label also includes a new oral suspension formulation of Promacta that is designed for younger children who may not be able to swallow tablets.
ITP affects as many as 5 in 100,000 children each year and is characterized [US] by a low platelet count.
Promacta is a once-daily oral thrombopoietin (TPO) receptor agonist that works by inducing stimulation and differentiation of megakaryocytes (large cells, found especially in bone marrow) from bone marrow stem cells to increase platelet production.
The label expansion of Promacta was based on data from two double-blind, placebo-controlled trials, including the largest Phase III clinical trial in this patient population.
Treatment with Promacta significantly increased and sustained platelet counts among pediatric [US] patients with chronic ITP with an insufficient response to prior chronic ITP therapies, and some patients taking concomitant ITP medications were able to reduce or discontinue their use of these medications, primarily corticosteroids.
Bruno Strigini, president, Novartis Oncology, said: “It's challenging and often very emotional for parents of a baby or toddler affected by a rare condition to manage their child's disease with limited treatment options.
"Today's label expansion for Promacta provides a new disease management option for families affected by chronic ITP and highlights our commitment to providing treatments for even the youngest children with rare diseases."